KTTAW Pasithea Therapeutics Corp.
0.0028USD-6.67%Mkt Cap: —P/E: —23d ago
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead produc…
Industry Peers
Biotechnology$127.47BUSDP/E 29.3
$78.65BUSD
$76.14BUSDP/E 18.3
$51.48BUSDP/E 31.2
$48.23BUSDP/E 31.4
$41.82BUSDP/E 17.8
$40.32BUSD
$39.83BUSDP/E 62.6
$32.48BUSDP/E 29.9
$30.04BUSDP/E 37.9
$24.71BUSD
$23.13BUSD
$22.85BUSDP/E 14.4
$22.17BUSDP/E 28.4
$21.94BUSD
$21.10BUSDP/E 29.1
$14.65BUSDP/E 17.1
$14.62BUSDP/E 18.6
$14.44BUSDP/E 15.2
$13.70BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-20.43M USD
Revenue/Share—
Last Price0.0028 USD
Fiscal Year End—
MR Quarter—
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)—
EPS (Forward)—
52W Range
0.00262% of range0.0109
52W High0.0109 USD
52W Low0.0026 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-36.99%
ROA-33.91%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.21M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-45.66M USD
Net Debt/EBITDA2.39
Balance Sheet
Debt/Equity—
Current Ratio26.25
Quick Ratio24.84
Book Value/Sh1.49 USD
Cash/Share1.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float19.68M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta0.29
S&P 52W Chg15.78%
Avg Vol (30d)8.68K
Avg Vol (10d)—
Technical Indicators
RSI (14)39.8
MACD-0.0019
MACD Signal-0.0014
MACD Hist.-0.0004
BB Upper0.0136 USD
BB Middle0.0072 USD
BB Lower0.0008 USD
BB Width178.29%
ATR (14)0.0020 USD
Vol Ratio (20d)2.18x